Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

methylphenidate HCl

- PMLiVE

Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma

Approximately 5,000 people are diagnosed with the disease every year in England

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

Pfizer’s Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients

More than 800,000 people globally are affected by the genetic blood disorder

- PMLiVE

Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma

Approximately 475 new cases of the disease are diagnosed in Scotland every year

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

Pfizer shares promising phase 3 results for RSV vaccine in immunocompromised adults

There are currently no RSV vaccines approved for adults aged 18 to 59 years in the US

- PMLiVE

Pfizer and BioNTech share late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links